A Comparative Evaluation of Mono-, Di- and Triglyceride of Medium Chain Fatty Acids by Lipid/Surfactant/Water Phase Diagram, Solubility Determination and Dispersion Testing for Application in Pharmaceutical Dosage Form Development

被引:105
作者
Prajapati, Hetal N. [1 ]
Dalrymple, Damon M. [2 ]
Serajuddin, Abu T. M. [1 ]
机构
[1] St Johns Univ, Coll Pharm & Allied Hlth Profess, Queens, NY 11439 USA
[2] ABITEC Corp, Columbus, OH 43215 USA
关键词
danazol; diglyceride; drug dispersion; drug solubility; lipid-based drug delivery; medium chain lipid; monoglyceride; phase diagram; triglyceride; DRUG-DELIVERY SYSTEMS; LIPID-BASED FORMULATIONS; WATER-SOLUBLE DRUGS; ORAL DELIVERY; NONIONIC SURFACTANT; RICH MEAL; BIOAVAILABILITY; MICROEMULSIONS; PHARMACOKINETICS; CYCLOSPORINE;
D O I
10.1007/s11095-011-0541-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose To compare physiochemical properties of mono-, di- and triglycerides of medium chain fatty acids for development of oral pharmaceutical dosage forms of poorly water-soluble drugs using phase diagrams, drug solubility, and drug dispersion experiments. Phase diagrams were prepared using a monoglyceride (glycerol monocaprylocaprate: Capmul MCMA (R) EP), a diglyceride (glycerol dicaprylate) and two triglycerides (glycerol tricaprylate: Captex 8000A (R); caprylic/capric triglycerides: Captex 355 EP/NFA (R)) in combination with a common surfactant (PEG-35 castor oil: Cremophor ELA (R)) and water. Psuedoternary phase diagrams using mixtures of monoglyceride with either diglyceride or triglyceride were constructed to determine any potential advantage of using lipid mixtures. The monoglyceride gave microemulsion (clear or translucent liquid) and emulsion phases, whereas di- and triglycerides exhibited an additional gel phase. Among individual mono-, di- and triglycerides, the oil-in-water microemulsion region was the largest for the diglyceride. Gel phase region within diglyceride and triglyceride phase diagrams could be practically eliminated and microemulsion regions expanded by mixing monoglyceride with di- or tri-glycerides (1:1). Addition of a model drug, danazol, had no effect on particle sizes of microemulsions formed. Dispersion of drug in aqueous media from mixtures of mono- and diglyceride or mono- and triglyceride was superior to individual lipids. Systematic study on comparison of mono-, di- and triglyceride of medium chain fatty acids will help formulators select components for optimal lipid-based formulation.
引用
收藏
页码:285 / 305
页数:21
相关论文
共 56 条
[11]   Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization [J].
Elnaggar, Yosra S. R. ;
El-Massik, Magda A. ;
Abdallah, Ossama Y. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 380 (1-2) :133-141
[12]  
Ezrahi S., 1999, Handb. Microemulsion Sci. Technol. N. Y. Inf. Inc, P185
[13]  
Gradzielski M., 1999, Handbook of Microemulsion Science and Technology, P357
[14]   Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs [J].
Gursoy, RN ;
Benita, S .
BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) :173-182
[15]   Oral lipid-based formulations [J].
Hauss, David J. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :667-676
[16]   Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor [J].
Hauss, DJ ;
Fogal, SE ;
Ficorilli, JV ;
Price, CA ;
Roy, T ;
Jayara, AA ;
Keirns, JJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (02) :164-169
[17]  
Hauss DJ, 2006, AM PHARM REV
[18]  
Humberstone AJ, 1997, ADV DRUG DELIVER REV, V25, P103, DOI 10.1016/S0169-409X(96)00494-2
[19]   Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs [J].
Kang, BK ;
Lee, JS ;
Chon, SK ;
Jeong, SY ;
Yuk, SH ;
Khang, G ;
Lee, HB ;
Cho, SH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 274 (1-2) :65-73
[20]   Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations [J].
Kaukonen, AM ;
Boyd, BJ ;
Porter, CJH ;
Charman, WN .
PHARMACEUTICAL RESEARCH, 2004, 21 (02) :245-253